Why Quoin Pharmaceuticals Is Rising In Pre-market?

rttnews
2025.10.21 12:47
portai
I'm PortAI, I can summarize articles.

Quoin Pharmaceuticals (QNRX) has seen an 8% rise in pre-market trading following the FDA's grant of Orphan Drug Designation for its lead product candidate, QRX003, aimed at treating Netherton Syndrome. This designation complements a similar one from the European Medicines Agency in May 2025. QRX003 is currently undergoing pivotal clinical trials, with enrollment expected to finish in Q1 2026 and top-line data anticipated in the latter half of 2026, leading to an NDA submission later that year.

Quoin Pharmaceuticals (QNRX) announced the FDA has granted Orphan Drug Designation to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. The designation follows previously granted Orphan Drug Designation by the European Medicines Agency in May 2025.

QRX003 lotion is being evaluated in two late-stage whole body pivotal clinical trials for Netherton Syndrome. Enrollment is expected to be completed in first quarter 2026, top-line data is anticipated in the second half of 2026, and NDA submission is planned later in the year.

Shares of Quoin are up 8% in pre-market trade on Tuesday.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.